Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa

Abstract

Summary Setting South Africa is one of the world’s 22 high tuberculosis (TB) burden countries, with the second highest number of notified rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB) cases. Objective To estimate patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB in South Africa. Design Patients diagnosed with RR-TB/MDR-TB and accessing care at government health care facilities were surveyed using a structured questionnaire. Direct and indirect costs associated with accessing RR-TB/MDR-TB care were estimated at different treatment durations for each patient. Results A total of 134 patients were surveyed: 84 in the intensive phase and 50 in the continuation phase of treatment, 82 in-patients and 52 out-patients. The mean monthly patient costs associated with the diagnosis and treatment of RR-TB/MDR-TB were higher during the intensive phase than the continuation phase (US$235 vs. US$188) and among in-patients than among out-patients (US$269 vs. US$122). Patients in the continuation phase and those accessing care as out-patients reported higher out-of-pocket costs than other patients. Most patients did not access social protection for costs associated with RR-TB/MDR-TB illness. Conclusion Despite free health care, patients bear high costs when accessing diagnosis and treatment services for RR-TB/MDR-TB; appropriate social protection mechanisms should be provided to assist them in coping with these costs.

Patient costs of hypertension care in public health care facilities in Kenya

“…First, the study was not nationally representative as it was carried out in five health facilities in two rural counties. Secondly, the use of an official minimum wage to estimate productivity loss for all patients could have potentially overestimated indirect costs among patients who were unemployed prior to their illness or underestimated indirect costs among those who were employed . Recall bias is a concern in patient cost surveys.…”

Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation

“…We estimated the direct and indirect costs incurred by study participants while accessing care from the reported start of tuberculosis symptoms 21, 22. In summary, three samples of patients were interviewed 21 .…”

“…We interviewed a further cohort of 168 patients on first-line tuberculosis treatment, who were not part of the XTEND cohort (to protect from interview overload), at 2 months and 5 months from start of treatment. Finally, we interviewed a cross-section of 134 patients with multidrug-resistant tuberculosis from Western Cape 22 . All respondents were asked about their health-seeking activities, the associated costs, income loss, the time cost of carers, and any coping strategies used.…”

Reasons for Non-Enrollment in Treatment among Multi-Drug Resistant Tuberculosis Patients in Hunan Province, China

“…Although the Global Fund Tuberculosis Program and NRCMS may cover almost all direct MDR-TB treatment expenses, patients still have to pay for other related testing fees and may be affected by lost wages, transportation costs and other indirect economic losses. As most MDR-TB patients have been shown to be particularly impoverished, they may choose to not enroll in treatment [9–11], Additional reasons for non-enrollment in treatment are discussed below.…”